[go: up one dir, main page]

EP2200627A4 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA - Google Patents

METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA

Info

Publication number
EP2200627A4
EP2200627A4 EP07814876A EP07814876A EP2200627A4 EP 2200627 A4 EP2200627 A4 EP 2200627A4 EP 07814876 A EP07814876 A EP 07814876A EP 07814876 A EP07814876 A EP 07814876A EP 2200627 A4 EP2200627 A4 EP 2200627A4
Authority
EP
European Patent Office
Prior art keywords
melanoma
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07814876A
Other languages
German (de)
French (fr)
Other versions
EP2200627A1 (en
Inventor
James S Goydos
Suzie Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Rutgers Health
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of EP2200627A1 publication Critical patent/EP2200627A1/en
Publication of EP2200627A4 publication Critical patent/EP2200627A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07814876A 2007-09-14 2007-09-14 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA Withdrawn EP2200627A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/078550 WO2009035460A1 (en) 2007-09-14 2007-09-14 Methods and compositions for treating melanoma

Publications (2)

Publication Number Publication Date
EP2200627A1 EP2200627A1 (en) 2010-06-30
EP2200627A4 true EP2200627A4 (en) 2013-01-09

Family

ID=40452289

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07814876A Withdrawn EP2200627A4 (en) 2007-09-14 2007-09-14 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA

Country Status (3)

Country Link
EP (1) EP2200627A4 (en)
AU (1) AU2007358742A1 (en)
WO (1) WO2009035460A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013262655A1 (en) * 2012-05-16 2014-12-04 John Wayne Cancer Institute Immunological markers for adjuvant therapy in melanoma

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATALLAH EHAB ET AL: "Treatment of metastatic malignant melanoma.", CURRENT TREATMENT OPTIONS IN ONCOLOGY MAY 2005, vol. 6, no. 3, May 2005 (2005-05-01), pages 185 - 193, XP002688037, ISSN: 1527-2729 *
EISEN T ET AL: "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis", BRITISH JOURNAL OF CANCER, vol. 95, no. 5, September 2006 (2006-09-01), pages 581 - 586, XP002688038, ISSN: 0007-0920 *
HAAS HELGA SUSANNE ET AL: "The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma", ONCOLOGY REPORTS, vol. 17, no. 6, June 2007 (2007-06-01), pages 1399 - 1404, XP002688036, ISSN: 1021-335X *
PATRICK TERHEYDEN ET AL: "Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER, BERLIN, DE, vol. 133, no. 11, 22 June 2007 (2007-06-22), pages 897 - 901, XP019542595, ISSN: 1432-1335, DOI: 10.1007/S00432-007-0251-8 *
See also references of WO2009035460A1 *

Also Published As

Publication number Publication date
AU2007358742A1 (en) 2009-03-19
EP2200627A1 (en) 2010-06-30
WO2009035460A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
FR23C1003I2 (en) Compositions and their uses for the treatment of Multiple Sclerosis
EP2209371A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY
EP2352517A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF COMPLEMENT RELATED DISORDERS
EP2200431A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP2214707A4 (en) COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION
EP2224955A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ARTHRITIS
EP2271301A4 (en) METHODS AND COMPOSITIONS FOR THE DELIVERY OF AGENTS
EP2470191A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
EP2320937A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR OXIDATION STRESS AND PIGMENT RETINITY
EP2627665A4 (en) METHODS AND COMPOSITIONS FOR TREATING HEMOPHILIA B
PL3354276T3 (en) COMPOSITIONS FOR THE TREATMENT OF GIASMATIS
EP2521913A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2182804A4 (en) METHODS OF TREATING DEPENDENCE
EP2627334A4 (en) METHODS AND COMPOSITIONS FOR POLYMERASE INHIBITION
EP2282719A4 (en) COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
EP2558085A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
EP2203057A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS
EP2429530A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATIVE AND ISCHEMIC DISORDERS
EP2419136A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP2247291A4 (en) METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY INTESTINAL INFECTION
EP2349320A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
PL2205720T3 (en) COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS
EP2498792A4 (en) METHODS AND COMPOSITIONS FOR THE RAPID TREATMENT OF AN EXTERNAL OTITE
EP2632550A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF HIV ASSOCIATED DIARRHEA
EP2217238A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEIN DISEASES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100412

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/197 20060101ALI20121128BHEP

Ipc: A61P 35/00 20060101ALI20121128BHEP

Ipc: A61K 31/365 20060101ALI20121128BHEP

Ipc: A61K 31/428 20060101AFI20121128BHEP

Ipc: A61K 45/06 20060101ALI20121128BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20121207

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130713